Dysregulation of monocyte biology in metabolic syndrome

Ishwarlal Jialal, Sridevi Devaraj, Uthra Rajamani

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Metabolic syndrome (MetS), which constitutes a cardio-metabolic risk cluster, is becoming a global epidemic. It is a pro-inflammatory and pro-oxidant state that confers an increased risk of cardiovascular disease and diabetes. MetS is not only characterized by increased circulating biomarkers of inflammation and oxidative stress but also by dysregulation of a pivotal phagocyte, the circulating monocyte. Pertubations manifesting in monocytes of patients with MetS include increased Toll-like receptors, CD40-CD40L dyad, increased ER stress, increased CCR5 and Fc-γ receptors (CD32 and CD64). Additionally, the monocytes demonstrate increase in NADPH oxidase activity and decreased Nrf2, resulting in oxidative damage to biomolecules. Thus the dysregulated monocyte in MetS appears to be a critical cell in the predisposition of MetS patients to diabetes and CVD. Therapeutic strategies targeting monocytes can attenuate this risk and the most compelling data derives from studies with statin therapy.

Original languageEnglish (US)
Pages (from-to)213-221
Number of pages9
JournalExpert Review of Endocrinology and Metabolism
Issue number3
StatePublished - 2014


  • Inflammation
  • Metabolic syndrome
  • Monocytes
  • NADPH oxidase
  • Oxidative stress
  • Toll-like receptors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Dysregulation of monocyte biology in metabolic syndrome'. Together they form a unique fingerprint.

Cite this